Testing CAR-T cell therapy for high-risk multiple myeloma or plasmacytoma
Tests CAR-T cells, made from a patient's own immune cells, in adults with high-risk myeloma.
Key facts
- Who runs it
- Shenzhen Geno-Immune Medical Institute
- Where
- Shenzhen, ChinaSee the site
- Trial code
- Registry title
- Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
- Status
- Not yet recruiting
- Phase
- Phase 1/2
- People taking part
- 20 people, planned
- Starts
- 31 Dec 2026
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Treatments tested
- CAR-T cells
- Record updated
- 2 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 80 with multiple myeloma or plasmacytoma, where the aim of treatment is a strictly complete remission. It tests CAR-T cell therapy as first-line treatment.
- Age
- 18 Years to 80 Years
- Sex
- Men and women can join.
- Disease stage
- Multiple myeloma or plasmacytoma, with strictly complete remission (sCR) as the treatment goal. The title says high-risk disease.
- Earlier treatment
- People who had an earlier autologous stem cell transplant (auto-SCT) can join, whatever other treatments they had.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Uncontrolled active infection
- Active HIV, hepatitis B or hepatitis C infection
- Taking steroids by mouth or injection at the same time (inhaled steroids are allowed)
- Expected survival of 12 weeks or less
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Male and female subjects with multiple myeloma or plasmacytoma
- Strictly complete remission (sCR) is a treatment goal
- Expected survival > 12 weeks
- After prior auto-SCT is eligible regardless of other prior therapies
- Adequate venous access for apheresis, and no other contraindications for leukapheresis
- Voluntary informed consent is given and commitment to continued follow-up
Who cannot take part
- Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary
- Uncontrolled active infection
- Active HIV, hepatitis B or hepatitis C infection
- Any medical conditions that may preclude participation
- Pregnant or lactating women
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in China
- Shenzhen Geno-immune Medical InstituteShenzhen, ChinaContact: Lung-Ji Chang, ph.DNo longer taking part
About the trial
What the trial wants to find out
The aim of this clinical trial is to assess the feasibility, safety, and efficacy of CAR-T cell therapy targeting multiple cancer cell antigens in high-risk multiple myeloma or plasmacytoma as part of a frontline treatment regimen for patients. Another goal of the study is to learn more about the persistence and function of these CAR-T cells in the body.
The group in the trial
- CAR-T cells to treat MMTreatment being tested
Treatment: CAR-T cells
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Frontline Management of High-Risk Multiple Myeloma or Plasmacytoma With BCMA and GPRC5D Combination CAR-T Cell Therapy
- Plain-language title
- Testing CAR-T cell therapy for high-risk multiple myeloma or plasmacytomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06429150, who can take part
- Record updated
- 2 November 2026